Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-021-02563-3
Abstract: Discovery and clinical development of monoclonal antibodies with the ability to interfere in the regulation of the immune response have significantly changed the landscape of oncology in recent years. Among the active agents licensed by… read more here.
Keywords: monoclonal antibodies; open question; oncology; dosage anti ... See more keywords